| Literature DB >> 29661877 |
Sangun Lee1, Melanie Ginese1, Gillian Beamer1, Hillary R Danz1, Donald J Girouard1, Susan P Chapman-Bonofiglio1, Minhee Lee1, Matthew A Hulverson2, Ryan Choi2, Grant R Whitman2, Kayode K Ojo2, Samuel L M Arnold2, Wesley C Van Voorhis2, Saul Tzipori3.
Abstract
Recent reports highlighting the global significance of cryptosporidiosis among children have renewed efforts to develop control measures. We evaluated the efficacy of bumped kinase inhibitor (BKI) 1369 in the gnotobiotic piglet model of acute diarrhea caused by Cryptosporidium hominis, the species responsible for most human cases. Five-day treatment with BKI 1369 reduced signs of disease early during treatment compared to those of untreated animals. Piglets treated with BKI 1369 exhibited significant reductions of oocyst excretion, mucosal colonization by C. hominis, and mucosal lesions, which resulted in considerable symptomatic improvement. BKI 1369 reduced the parasite burden and disease severity in the gnotobiotic pig model. Together these data suggest that a BKI-mediated therapeutic may be an effective treatment against cryptosporidiosis.Entities:
Keywords: BKI 1369; Cryptosporidium hominis; bumped kinase inhibitor; gnotobiotic pigs
Mesh：
Substances：
Year: 2018 PMID： 29661877 PMCID： PMC6021680 DOI： 10.1128/AAC.00147-18
Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN： 0066-4804 Impact factor: 5.191